A Phase 3 interventional study of 1.0mg/kg/day PRAX-562 and 1.5mg/kg/day PRAX-562 in Developmental and Epileptic Encephalopathy 1, sponsored by Praxis Precision Medicines. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Praxis Precision Medicines · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 793 studies in Epilepsy with a site in United States — 159 open to participants now, 194 under way, 17 of them phase 3. Epilepsy · United States.
Among the 793 studies in Epilepsy with a site in United States, this one is the 124th largest by planned enrollment of the 588 interventional ones that give a count, is one of 36 that started in 2025, is one of 126 in phase 3, reaches primary completion later than 43 of the 191 other live ones, and was the 741st registered.
1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.
Browse Epilepsy studies →159 of the 793 studies in Epilepsy with a site in United States are open now. Recruiting first, the newest first:
Cadence Neuroscience · Sites in United States
Ages 7+ · Men only
Duke University · Sites in United States
Ages 18–70
NeuroOne Medical Technologies Corporation · Sites in United States
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 13–29
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.
This study: 2 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
793 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 82 · Phase 2 126 · Phase 3 133 · Phase 4 51
First in 1975; this study’s year is marked. 36 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.
Median enrollment 40 across the 588 interventional studies, 90 across the 193 observational. Of the 526 that completed or were terminated, 243 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 793 have an industry lead sponsor. The 10 most frequent:
Praxis Precision Medicines is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Praxis Precision Medicines has 5 studies filed under Epilepsy — fewer than ten, so there is no comparison to draw.
72 of the studies in Epilepsy with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07010471Phase 3Praxis Precision MedicinesA Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | 2026-12 |
| NCT07019922Phase 3Praxis Precision MedicinesA Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | 2026-12 |
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT05431595Phase 3M.D. Anderson Cancer CenterManaging Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy | 2027-02-02 |
Add all 72 to your calendar (.ics) → With an account.
Among the 793 studies in Epilepsy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will be randomly assigned in a double-blind manner and a 1:1 ratio to receive 1.0mg-1.5mg/kg relutrigine or placebo once daily orally or gastronomy/jejunostomy for 16 weeks
Drug: 1.0mg/kg/day PRAX-562 · Drug: 1.5mg/kg/day PRAX-562
Eligible participants will be randomly assigned in a double-blind manner and a 1:1 ratio to receive 1.0mg-1.5mg/kg relutrigine or placebo once daily orally or gastronomy/jejunostomy for 16 weeks
Drug: Placebo
Participants from Part A will have the option to rollover to Part B to receive 1.0mg-1.5mg/kg of relutrigine once daily orally or gastronomy/jejunostomy for 32 weeks
Drug: 1.0mg/kg/day PRAX-562 · Drug: 1.5mg/kg/day PRAX-562
Once daily orally or gastronomy/jejunostomy
Also known as: relutrigine
Once daily orally or gastronomy/jejunostomy
Once daily orally or gastronomy/jejunostomy
To assess the effect of relutrigine on seizure frequency in participants with DEEs compared to placebo
Change from baseline in monthly motor seizure frequency
Time frame: 16 weeks
Achieve >50% reduction in monthly seizure frequency from baseline
Proportion of patients achieving \>50% reduction in monthly seizure frequency from baseline
Time frame: 16 weeks
Change in seizure-free days
Change in seizure-free days from baseline
Time frame: 16 weeks
Clinical Global Impression-Severity questionnaire
CGI-S at baseline after 16 weeks
Time frame: 16 weeks
Clinical Global Impression-Improvement questionnaire
CGI-I subdomains scores after 16 weeks
Time frame: 16 weeks
Caregiver Global Impression-Severity questionnaire
CgGI-S at baseline after 16 weeks
Time frame: 16 weeks
Caregiver Global Impression-Improvement questionnaire
CgGI-I subdomains scores after 16 weeks
Time frame: 16 weeks
To evaluate the safety and tolerability of relutrigine in participants with DEEs
Incidence and severity of TEAEs
Time frame: 16 weeks
Columbia-Suicide Severity Rating Scale questionnaire
Incidence of suicidal ideation or behavior as measured by the C-SSRS
Time frame: 16 weeks
Evaluate the safety and tolerability of relutrigine in participants with DEEs
Incidence of clinically significant ECG abnormalities
Time frame: 16 weeks
To evaluate the safety labs and tolerability of relutrigine in participants with DEEs
The principal investigator (PI) or sub investigator will review the laboratory report and document this review. Any clinically significant adverse changes occurring during the clinical trial will be documented as adverse events.
Time frame: 16 weeks
To evaluate the change in respiratory rate and tolerability of relutrigine in participants with DEEs
Change in respiratory rate in breaths per minute
Time frame: 16 weeks
To evaluate the change in blood pressure and tolerability of relutrigine in participants with DEEs
Change in blood pressure in mm/Hg
Time frame: 16 weeks
To evaluate the change in pulse and tolerability of relutrigine in participants with DEEs
Change in heart rate in beats per minute
Time frame: 16 weeks
To evaluate the change in body temperature and tolerability of relutrigine in participants with DEEs
Change in tympanic temperature in Celsius
Time frame: 16 weeks
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 17 months is below that.
Counting every sponsor, half of 86 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Praxis Precision Medicines